Search

Displaying results 1401 - 1410 of 2674 in total
  1. Drug

    Ammonia

    go.drugbank.com/drugs/DB11118
    ApprovedInvestigational

    Ammonia is a naturally-occurring compound with a chemical formula NH3 and structure of trigonal pyramidal geometry. It is a colorless gas with a pungent smell, and become NH4, or ammonium ion, when in water. Although ammonia is used as a...

  2. Drug

    Trifluridine

    go.drugbank.com/drugs/DB00432
    ApprovedInvestigational

    Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to idoxuridine . It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epitheli...

  3. Drug

    Ferrous asparto glycinate

    go.drugbank.com/drugs/DB11169
    Approved

    Ferrous asparto glycinate is an iron-amino acid chelate. It is available as a dietary supplement used in the treatment of iron deficiency and iron deficiency anemia.

    Mixtures: FeRiva FA
  4. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. DB00135 is a non-essential amino acid with a polar side group. N-acetyltyrosine is administered as parenteral nutrition or intravenou...

  5. Drug

    Oritavancin

    go.drugbank.com/drugs/DB04911
    ApprovedInvestigational

    [A39384,A193482,L8492] On March 12, 2021 the FDA approved Kimyrsa, a complete course of therapy in a single, 1 hour 1200 mg infusion. … [L32634] Orbactiv, the other FDA approved oritavancin product, is administered over a 3 hour infusion and contains a lower dose of 400 mg.

  6. Drug

    Pegaptanib

    go.drugbank.com/drugs/DB04895
    ApprovedWithdrawn

    Pegaptanib was granted FDA approval on 17 September 2004.[L17903]

  7. Drug

    Tolvaptan

    go.drugbank.com/drugs/DB06212
    ApprovedInvestigational

    FDA approved on May 19, 2009.

    Categories: Antidiuretic Hormone Receptor Antagonists, Vasopressin V2 Receptor Antagonist
  8. Drug

    Glyburide

    go.drugbank.com/drugs/DB01016
    ApprovedInvestigational

    [A183617] Glyburide was granted FDA approval on 1 May 1984.[L8117] A formulation with metformin was granted FDA approval on on 31 July 2000.[L8120]

  9. Drug

    Pembrolizumab

    go.drugbank.com/drugs/DB09037
    ApprovedInvestigational

    [L38934,L43257] In September 2025, the US FDA approved a formulation of pembrolizumab that includes [berahyaluronidase alfa] (Keytruda QLEX) to allow for subcutaneous administration.[L54026] … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.

    Categories: Programmed Death Receptor-1 Blocking Antibody, Programmed Death Receptor-1-directed Antibody Interactions
  10. Drug

    Phentermine

    go.drugbank.com/drugs/DB00191
    ApprovedIllicitInvestigational

    [A174367] Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960.